Cargando…

Genetic markers in oligodendroglial tumours

BACKGROUND: Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5–20% of all gliomas. CONCLUSIONS: Oligodendroglial tumours with 1p and 19q loss demonstrate a bett...

Descripción completa

Detalles Bibliográficos
Autores principales: Velnar, Tomaz, Smrdel, Uros, Popovic, Mara, Bunc, Gorazd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423675/
https://www.ncbi.nlm.nih.gov/pubmed/22933885
http://dx.doi.org/10.2478/v10019-010-0007-y
_version_ 1782241126417170432
author Velnar, Tomaz
Smrdel, Uros
Popovic, Mara
Bunc, Gorazd
author_facet Velnar, Tomaz
Smrdel, Uros
Popovic, Mara
Bunc, Gorazd
author_sort Velnar, Tomaz
collection PubMed
description BACKGROUND: Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5–20% of all gliomas. CONCLUSIONS: Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice.
format Online
Article
Text
id pubmed-3423675
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Versita, Warsaw
record_format MEDLINE/PubMed
spelling pubmed-34236752012-08-29 Genetic markers in oligodendroglial tumours Velnar, Tomaz Smrdel, Uros Popovic, Mara Bunc, Gorazd Radiol Oncol Review BACKGROUND: Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5–20% of all gliomas. CONCLUSIONS: Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice. Versita, Warsaw 2010-03-18 2010-03 /pmc/articles/PMC3423675/ /pubmed/22933885 http://dx.doi.org/10.2478/v10019-010-0007-y Text en Copyright © by Association of Radiology & Oncology http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Velnar, Tomaz
Smrdel, Uros
Popovic, Mara
Bunc, Gorazd
Genetic markers in oligodendroglial tumours
title Genetic markers in oligodendroglial tumours
title_full Genetic markers in oligodendroglial tumours
title_fullStr Genetic markers in oligodendroglial tumours
title_full_unstemmed Genetic markers in oligodendroglial tumours
title_short Genetic markers in oligodendroglial tumours
title_sort genetic markers in oligodendroglial tumours
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423675/
https://www.ncbi.nlm.nih.gov/pubmed/22933885
http://dx.doi.org/10.2478/v10019-010-0007-y
work_keys_str_mv AT velnartomaz geneticmarkersinoligodendroglialtumours
AT smrdeluros geneticmarkersinoligodendroglialtumours
AT popovicmara geneticmarkersinoligodendroglialtumours
AT buncgorazd geneticmarkersinoligodendroglialtumours